Skip to main content
SpringerLink
Log in

Bootstrap Analyses of Cost Effectiveness in Antidepressant Pharmacotherapy

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

In this study, we describe ‘bootstrap’ methodology for placing statistical confidence limits around an incremental cost effectiveness ratio (ICER). This approach was applied to a retrospective study of annual charges for patients undergoing pharmacotherapy for depression.

We used MarketScanSM(service mark) data from 1990 to 1992, which includes medical and pharmacy claims for a privately insured group of employed individuals and their families in the US. Our primary effectiveness measure was the proportion of patients who remained stable on their initial antidepressant medication for at least 6 consecutive months. Our primary cost measure was the total annual charge incurred by patients taking the selective serotonin reuptake inhibitor fluoxetine, a tricyclic antidepressant or a heterocyclic antidepressant.

On average, fluoxetine pharmacotherapy tended to decrease annual charges by $US16.48 per patient for each percentage increase in depressed patients remaining stable on initial pharmacotherapy for 6 months, resulting in a negative ICER point-estimate. However, the upper ICER confidence limit is positive, which means that fluoxetine treatment may possibly increase annual per patient charges. With 95% confidence, any such increase was no more than $US130 per patient for each percentage increase in patients remaining stable on initial pharmacotherapy for at least 6 months.

One advantage of using a bootstrap approach to ICER analysis is that it does not require restrictive distributional assumptions about cost and outcome measures. Bootstrapping also yields a dramatic graphical display of the variability in cost and effectiveness outcomes that result when a study is literally ‘redone’ hundreds of times. This graphic also displays the ICER confidence interval as a ‘wedge-shaped’ region on the cost-effectiveness plane. In fact, bootstrapping is easier to explain and appreciate than the elaborate calculations and approximations otherwise involved in ICER estimation.

Our discussion addresses key technical questions, such as the role of logarithmic transformation in symmetrising highly skewed cost distributions. We hope that our discussion contributes to a dialogue, leading ultimately to a consensus on analysis of ICERs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care [working paper]. Association for Health Services Research Meeting; 1995 Jun 9; Chicago (IL). Indianapolis (IN): Eli Lilly and Company, 1996

    Google Scholar 

  2. Crown W, Lair TJ, Engelhart L, et al. The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization [working paper]. Washington DC: The MedStat Group, 1996

    Google Scholar 

  3. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716–21

    Article  PubMed  CAS  Google Scholar 

  4. Anderson JP, Bush JW, Chen M, et al. Policy state areas and properties of benefit-cost/utility analysis. JAMA 1986; 255: 794–5

    Article  PubMed  CAS  Google Scholar 

  5. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212–4

    Article  PubMed  CAS  Google Scholar 

  6. O’Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 30: 231–43

    Google Scholar 

  7. Willan AR, O’Brien BJ. Cost-effectiveness in clinical trials: from deterministic to stochastic models. Proceedings of the Biopharmaceutical Section of the America Statistical Association: 1994; Toronto, 19–28

  8. Sacristan JA, Day SJ, Navarro O, et al. Use of confidence intervals and sample size calculations in health economic studies. Ann Pharmacother 1995; 29: 719–25

    PubMed  CAS  Google Scholar 

  9. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med 1996; 15: 1447–58

    Article  PubMed  CAS  Google Scholar 

  10. Efron B, Gong G. A leisurely look at the bootstrap, jackknife and cross-validation. Am Statistician 1983; 37: 36–48

    Google Scholar 

  11. Efron B. An introduction to the bootstrap. New York: Chapman and Hall, 1993

    Google Scholar 

  12. Westfall PH, Young SS. Resampling-based multiple testing. New York: John Wiley and Sons, 1992

    Google Scholar 

  13. SAS Institute, Inc. Technical report P-229, SAS/STAT Software: changes and enhancements, release 6.07 [Chapter 17: Procedure MULTTEST, 371–405]. Cary (NC): SAS Institute, Inc., 1992

    Google Scholar 

  14. Obenchain RL. ICERconf: highly portable C-language source code for confidence intervals on incremental cost-effectiveness ratio slopes and angles. Pharmaceutical Research and Manufacturers of America (PhRMA), 1996

    Google Scholar 

  15. Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness of an episode of major depression. Am J Psychiatry 1992; 149: 795–800

    PubMed  CAS  Google Scholar 

  16. AHCPR Guidelines. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993; 150 (2 Suppl.): 1–26

    Google Scholar 

  17. Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA 1995; 273: 51–8

    Article  PubMed  CAS  Google Scholar 

  18. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49: 761–8

    Article  PubMed  CAS  Google Scholar 

  19. Berndt ER, Finkelstein SN, Greenberg PE, et al. Workplace performance effects from chronic depression and its treatment. Annual Meeting of the American Economic Association: 1996 Jan 6; San Francisco

  20. Heckman J. Sample selection as a specification error. Econometrica 1979; 47(1): 153–61

    Article  Google Scholar 

  21. L’Ecuyer P. Efficient and portable combined random number generators. Communications of the Association for Computing Machinery 1988; 31: 742–9, 774

    Article  Google Scholar 

  22. Chisholm J, Thomborson C. Public domain C-language source code (LECRAND/SETRAN/CHECKRAN) to generate, seed and check the L’Ecuyer random number generation algorithm, 1991

  23. Press WH, Flannery BP, Teukolsky SA, et. al. Random number generation. In: Numerical recipes in C: the art of scientific computing. Cambridge: Cambridge University Press, 1988

    Google Scholar 

  24. LaPierre Y, Bentkover J, Schaimbaum S, et al. Direct cost of depression: Analysis of treatment costs of paroxetine versus imipramine in Canada. Can J Psychiatry 1995; 40: 370–7

    PubMed  CAS  Google Scholar 

  25. Revicki DA, Brown RE, Palmer W, et al. Modeling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics 1995; 8: 524–40

    Article  PubMed  CAS  Google Scholar 

  26. LePen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs. tricyclics. J Affect Disord 1994; 31: 1–18

    Article  CAS  Google Scholar 

  27. Einarson TR, Arikian S, Sweeney S, et al. A model to evaluate the cost effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995; 17: 136–53

    Article  PubMed  CAS  Google Scholar 

  28. Boyer WF, Feighnew JP. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients. In: Jonsson B, Rosenbaum J, editors. Health economics of depression. London: John Wiley & Son Ltd., 1993: 65–75

    Google Scholar 

  29. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665–73

    Article  PubMed  CAS  Google Scholar 

  30. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16: 715–30

    PubMed  CAS  Google Scholar 

  31. Skaer TL, Sclar DA, Robison LM, et al. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res 1995; 56: 556–67

    Article  Google Scholar 

  32. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897–902

    Article  PubMed  CAS  Google Scholar 

  33. Heyde CC. Limit theorem, central. In: Johnson NL, Kotz J, Read CB, editors. Encyclopedia of statistical sciences. Vol 4. New York: John Wiley and Sons, 1982: 651–5

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 1850, Indianapolis, IN, 46285-0001, USA

    Robert L. Obenchain, Catherine A. Melfi, Thomas W. Croghan & Don P. Buesching

  2. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA

    Robert L. Obenchain, Catherine A. Melfi & Thomas W. Croghan

Authors
  1. Robert L. Obenchain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine A. Melfi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas W. Croghan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Don P. Buesching
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert L. Obenchain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Obenchain, R.L., Melfi, C.A., Croghan, T.W. et al. Bootstrap Analyses of Cost Effectiveness in Antidepressant Pharmacotherapy. PharmacoEconomics 11, 464–472 (1997). https://doi.org/10.2165/00019053-199711050-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199711050-00008

Keywords

Search

Navigation